80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Seasonal Allergic Rhinitis
Conditions
Seasonal Allergic Rhinitis
Trial Timeline
Nov 1, 2008 โ Feb 1, 2009
NCT ID
NCT00790023About 80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00790023. Target conditions include Seasonal Allergic Rhinitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00790023 | Phase 3 | Completed |
Competing Products
20 competing products in Seasonal Allergic Rhinitis